Generic Medicine Info
May be taken with or without food.
Acute dysentery (characterised by bloody stools and high fever), acute ulcerative colitis, abdominal pain without diarrhoea, bacterial enterocolitis caused by invasive organisms (e.g. Salmonella, Shigella, Campylobacter), pseudomembranous colitis associated with the use of broad-spectrum antibiotics; conditions wherein inhibition of peristalsis must be avoided (e.g. ileus, megacolon, toxic megacolon, constipation, abdominal distension).
Special Precautions
Patient with AIDS, history of drug abuse, risk factors for QT interval prolongation (e.g. congenital long QT syndrome, history of cardiac arrhythmias or other heart conditions, electrolyte abnormalities). Not recommended to be used for prolonged periods until the underlying cause of the diarrhoea has been investigated. Hepatic impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, drowsiness or tiredness, if affected, do not drive or operate machinery. Monitoring Parameters Assess for the cause of diarrhoea prior to treatment. Closely monitor for signs of CNS toxicity, particularly in patients with hepatic impairment.
Adverse Reactions
Significant: Gastrointestinal effects (e.g. constipation, abdominal pain or distension, blood in stool, ileus, toxic megacolon, acute pancreatitis), syncope, ventricular tachycardia. Rarely, anaphylaxis and anaphylactic shock. Eye disorders: Rarely, miosis. General disorders and administration site conditions: Rarely, fatigue. Gastrointestinal disorders: Flatulence, nausea, dry mouth, abdominal cramps or discomfort, vomiting, dyspepsia. Nervous system disorders: Dizziness, headache, somnolence. Rarely, stupor, depressed level of consciousness, coordination abnormality. Renal and urinary disorders: Rarely, urinary retention. Skin and subcutaneous tissue disorders: Rash. Rarely, pruritus, Stevens-Johnsons syndrome, toxic epidermal necrolysis.
Potentially Fatal: Serious CV events (e.g. QT and QRS complex prolongation, torsades de pointes, cardiac arrest), particularly in higher than recommended doses.
Drug Interactions
Concomitant use with inhibitors of P-glycoprotein (e.g. ritonavir, quinidine), CYP3A4 (e.g. ketoconazole, itraconazole), and CYP2C8 (e.g. gemfibrozil) increase loperamide plasma concentrations. May increase the plasma levels of oral desmopressin. Increased risk of serious CV events with agents known to prolong QT interval (e.g. procainamide, amiodarone, haloperidol, moxifloxacin).
CIMS Class
ATC Classification
A07DA03 - loperamide ; Belongs to the class of antipropulsives. Used in the treatment of diarrhea.
Disclaimer: This information is independently developed by CIMS based on loperamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in